Top GLP-1 & Obesity Drug Stocks
Obesity affects over 1 billion people globally, yet effective pharmacological treatment barely existed before GLP-1 drugs. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have demonstrated not just weight loss but cardiovascular, kidney, and liver benefits — expanding their use far beyond initial indications. The GLP-1 market is projected to reach $150B+ by 2030.
Eli Lilly's tirzepatide (Mounjaro/Zepbound) is the most effective approved GLP-1 drug by weight loss magnitude. Lilly is investing aggressively in manufacturing capacity to meet demand that significantly exceeds supply.
Strong price momentum (+55% over 1Y), a top-tier AI score (76), and the highest analyst upside in the group (+12% to target).
Novo Nordisk invented semaglutide (Ozempic/Wegovy) and generated over $25B from GLP-1 products in 2024. Its SELECT cardiovascular outcome trial results position Wegovy for broad cardiometabolic use beyond weight loss.
The most attractive valuation in the group (2x forward P/E), though a below-average AI score (38) and weak 1-year momentum (-12%).
Amgen's MariTide (AMG133) is a monthly injectable GLP-1/GIPR antagonist with differentiated monthly dosing. Phase 3 data could confirm it as a meaningful GLP-1 market entrant.
Strong price momentum (+56% over 1Y) and attractive valuation (18x forward P/E), though a below-average AI score (49) and analyst targets below the current price (-10%).
AbbVie has an oral GLP-1 (AZD5004 partner candidate) and a broad cardiometabolic pipeline. Its diversified revenue base reduces single-drug concentration risk while providing GLP-1 optionality.
Solid 1-year momentum (+20%), moderate upside to target (+8%), and attractive valuation (16x forward P/E).
Regeneron is developing bispecific antibodies targeting obesity-related pathways. Its strong R&D capability and Sanofi partnership give it resources to compete in the metabolic disease space.
Strong price momentum (+46% over 1Y) and attractive valuation (13x forward P/E), though a below-average AI score (43).
Moderna is applying its mRNA platform to metabolic diseases including obesity and cardiovascular conditions. Early-stage, but the platform applicability to GLP-1 targets is a longer-term catalyst.
Strong price momentum (+499% over 1Y), though analyst targets below the current price (-23%).
Continuous glucose monitors from Dexcom are standard-of-care for patients on GLP-1 therapies. As GLP-1 adoption expands, CGM penetration grows in tandem — making Dexcom a high-purity infrastructure play.
A below-average AI score (48) and limited near-term upside (+4% to target) weigh on the profile.
Danaher's bioprocessing equipment (Cytiva) is essential for manufacturing GLP-1 biologics at scale. As Lilly and Novo Nordisk race to expand capacity, Danaher is a key equipment supplier.
A below-average AI score (50).
| Stock | Rev Growth | Fwd P/E | Op Margin | 1Y Return | AI Score | Analyst Upside |
|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | +47.7% | 24.9x | +54.2% | +54.7% | 76 | +12.0% |
| NVO Novo Nordisk A/S | +2.1% | 2.1x | +42.5% | -12.5% | 38 | +1.2% |
| ABBV AbbVie Inc. | +10.2% | 15.7x | +40.0% | +20.4% | 52 | +8.3% |
| AMGN Amgen Inc. | +9.5% | 17.7x | +35.5% | +56.1% | 49 | -10.2% |
| REGN Regeneron Pharmaceuticals | +16.7% | 13.1x | +33.1% | +45.9% | 43 | +5.8% |
| MRNA Moderna, Inc. | +2.1% | -30.1x | -5.6% | +499.5% | 51 | -22.7% |
| DHR Danaher Corporation | +5.5% | 23.2x | +19.8% | +4.3% | 50 | +5.5% |
| DXCM Dexcom, Inc. | +13.1% | 29.1x | +24.3% | +8.8% | 48 | +3.6% |
- GLP-1 cardiovascular and kidney benefits drive broad label expansions beyond obesity
- Oral GLP-1 drugs (Lilly, Novo, others) dramatically expand the addressable patient population
- Emerging markets (China, India) begin GLP-1 adoption, adding billions to total addressable market
- Supply constraints ease by 2026-27, allowing prescription volumes to finally match latent demand
- Discontinuation rates remain high as patients stop taking GLP-1s due to side effects or cost
- Insurance coverage gaps limit US penetration despite massive demand and awareness
- Generic or biosimilar entry for semaglutide creates pricing pressure earlier than expected
- Next-generation oral GLP-1 competition from multiple entrants commoditizes the category
- LLY and NVO trade at premium valuations — any clinical setback or guidance miss is severely punished
- Payer pushback on GLP-1 reimbursement remains a headwind to penetration in commercial insurance
- Supply chain execution risk — manufacturing at GLP-1 scale requires billions in new plant investment
- Long-term safety data is still accumulating; any unexpected adverse finding would be market-moving
Prefer passive exposure to this theme? These ETFs provide broad coverage without individual stock selection.
Full valuation workups for the stocks in this theme — seven-method valuation, AI Score, and a 5-year Monte Carlo forecast.
Frequently Asked Questions
What are GLP-1 stocks?+
GLP-1 stocks are shares in pharmaceutical companies developing or manufacturing GLP-1 receptor agonist drugs — the class of medications that includes Ozempic, Wegovy, Mounjaro, and Zepbound. These drugs treat obesity, type 2 diabetes, and increasingly, cardiovascular and metabolic conditions.
Is Eli Lilly or Novo Nordisk the better GLP-1 investment?+
Both LLY and NVO are leading GLP-1 stocks. Lilly's tirzepatide (dual GLP-1/GIP agonist) demonstrates superior weight loss efficacy. Novo Nordisk's semaglutide has a longer commercial track record and broader cardiovascular outcome data. Valuation, pipeline depth, and manufacturing capacity are key differentiators.
What is the GLP-1 market size by 2030?+
Major investment banks and healthcare analysts project the GLP-1 market could reach $130–150B+ in annual revenue by 2030, driven by obesity, type 2 diabetes, and expanding cardiovascular indications. Oral GLP-1 formulations from Eli Lilly, Novo Nordisk, and others could dramatically expand the addressable patient population beyond injectable-tolerant patients, potentially pushing total market estimates higher than current projections.
What are the best obesity drug stocks besides LLY and NVO?+
Beyond Eli Lilly and Novo Nordisk, the most tracked obesity drug stocks include Amgen (AMGN) for MariTide — a differentiated monthly GLP-1/GIPR antagonist in Phase 3 — and Regeneron (REGN) for its bispecific antibody program targeting obesity pathways. Dexcom (DXCM) is an obesity infrastructure play as continuous glucose monitoring expands alongside GLP-1 prescription growth. Viking Therapeutics (VKTX) is a higher-risk, earlier-stage pipeline name frequently discussed but not included here due to its speculative stage.
Will GLP-1 drugs face generic competition?+
Semaglutide (Ozempic/Wegovy) is protected by patents that expire in the early-to-mid 2030s in major markets, with Novo Nordisk filing continuation patents on formulations and delivery mechanisms. Tirzepatide (Mounjaro/Zepbound) has a similar multi-year patent runway. Generic GLP-1 peptides are also technically complex to manufacture as biologics — biosimilar entry is more likely than traditional small-molecule generics, but biosimilar development for injectable GLP-1s requires significant investment and is years away from material market impact.
Why did Pfizer's GLP-1 drug fail?+
Pfizer's danuglipron — an oral GLP-1 receptor agonist — failed its Phase 3 clinical program due to tolerability issues, primarily nausea and vomiting at doses required for therapeutic weight loss. The failure reinforced the challenge of oral GLP-1 formulation: achieving sufficient drug exposure to drive weight loss with acceptable side effects at doses patients tolerate. Eli Lilly's orforglipron and Novo Nordisk's oral semaglutide (Rybelsus) have demonstrated more favorable tolerability profiles, keeping the oral GLP-1 opportunity alive despite Pfizer's exit.
Is GLP-1 a good long-term investment theme?+
The GLP-1 investment theme has multi-decade tailwinds: obesity affects 1B+ people globally, existing market penetration is low, new indications (cardiovascular, kidney, liver, Alzheimer's) are expanding the addressable patient population, and oral formulations could broaden access significantly. The primary risks are valuation (LLY and NVO trade at large premiums to the S&P 500), insurance coverage gaps limiting US penetration, and the possibility that next-generation therapies (AMG133, bispecifics, orals from multiple companies) commoditize the category. For long-term investors comfortable with premium healthcare valuations, GLP-1 remains one of the most durable pharmaceutical themes of the decade.
Sign in to BriMindInvest to compare any two stocks with live metrics, AI scores, valuation charts, and personalised insights.